NR565 ADVANCED PHARMACOLOGY
COMPREHENSIVE EXAM REVIEW
(VERIFIED AND CORRECT Q & A)
SATISFACTION GUARANTEED 2026/2027
CHAMBERLAIN
1. A patient is prescribed Warfarin for atrial fibrillation and is now started on Fluconazole for
a fungal infection. What is the most likely pharmacological outcome?
A. Decreased anticoagulant effect of Warfarin
B. No significant interaction occurs
C. Decreased antifungal effect of Fluconazole
D. Increased anticoagulant effect of Warfarin
Answer: D
Conceptual Explanation: Fluconazole is a potent inhibitor of the CYP2C9 enzyme, which is
responsible for the metabolism of the more potent S-isomer of Warfarin. Inhibition leads to
increased Warfarin levels and increased risk of bleeding.
2. When assessing the steady-state concentration of a drug with a half-life of 12 hours, how
long will it take for the drug to reach approximately 94% of its steady-state level?
A. 12 hours
,B. 48 hours
C. 24 hours
D. 60 hours
Answer: B
Conceptual Explanation: It takes approximately 4 to 5 half-lives to reach steady state. 4
half-lives * 12 hours = 48 hours (93.75%).
3. Which pharmacokinetic process is most significantly affected by the ‘first-pass effect’ when
a drug is administered orally?
A. Distribution
B. Excretion
C. Metabolism
D. Absorption
Answer: C
Conceptual Explanation: The first-pass effect refers to the rapid hepatic metabolism of an
orally administered drug before it reaches the systemic circulation.
4. A patient is taking Digoxin 0.125mg daily. Which electrolyte abnormality most significantly
increases the risk of Digoxin toxicity even if the Digoxin level is within the therapeutic range?
A. Hypokalemia
B. Hypocalcemia
, C. Hyperkalemia
D. Hypernatremia
Answer: A
Conceptual Explanation: Hypokalemia increases Digoxin binding to the Na+/K+ ATPase
pump, thereby increasing the risk of toxicity.
5. What is the mechanism of action of ACE inhibitors in the management of heart failure?
A. Inhibits the conversion of Angiotensin I to Angiotensin II
B. Directly blocks beta-1 receptors in the heart
C. Antagonizes aldosterone receptors in the distal tubule
D. Increases the force of myocardial contraction
Answer: A
Conceptual Explanation: ACE inhibitors block the Angiotensin Converting Enzyme,
preventing the formation of Angiotensin II, a potent vasoconstrictor and stimulator of
aldosterone.
6. Which of the following is a major contraindication for the use of Metformin in patients
with Type 2 Diabetes?
A. eGFR less than 30 mL/min/1.73m2
B. History of hypertension
C. Body Mass Index (BMI) greater than 30
COMPREHENSIVE EXAM REVIEW
(VERIFIED AND CORRECT Q & A)
SATISFACTION GUARANTEED 2026/2027
CHAMBERLAIN
1. A patient is prescribed Warfarin for atrial fibrillation and is now started on Fluconazole for
a fungal infection. What is the most likely pharmacological outcome?
A. Decreased anticoagulant effect of Warfarin
B. No significant interaction occurs
C. Decreased antifungal effect of Fluconazole
D. Increased anticoagulant effect of Warfarin
Answer: D
Conceptual Explanation: Fluconazole is a potent inhibitor of the CYP2C9 enzyme, which is
responsible for the metabolism of the more potent S-isomer of Warfarin. Inhibition leads to
increased Warfarin levels and increased risk of bleeding.
2. When assessing the steady-state concentration of a drug with a half-life of 12 hours, how
long will it take for the drug to reach approximately 94% of its steady-state level?
A. 12 hours
,B. 48 hours
C. 24 hours
D. 60 hours
Answer: B
Conceptual Explanation: It takes approximately 4 to 5 half-lives to reach steady state. 4
half-lives * 12 hours = 48 hours (93.75%).
3. Which pharmacokinetic process is most significantly affected by the ‘first-pass effect’ when
a drug is administered orally?
A. Distribution
B. Excretion
C. Metabolism
D. Absorption
Answer: C
Conceptual Explanation: The first-pass effect refers to the rapid hepatic metabolism of an
orally administered drug before it reaches the systemic circulation.
4. A patient is taking Digoxin 0.125mg daily. Which electrolyte abnormality most significantly
increases the risk of Digoxin toxicity even if the Digoxin level is within the therapeutic range?
A. Hypokalemia
B. Hypocalcemia
, C. Hyperkalemia
D. Hypernatremia
Answer: A
Conceptual Explanation: Hypokalemia increases Digoxin binding to the Na+/K+ ATPase
pump, thereby increasing the risk of toxicity.
5. What is the mechanism of action of ACE inhibitors in the management of heart failure?
A. Inhibits the conversion of Angiotensin I to Angiotensin II
B. Directly blocks beta-1 receptors in the heart
C. Antagonizes aldosterone receptors in the distal tubule
D. Increases the force of myocardial contraction
Answer: A
Conceptual Explanation: ACE inhibitors block the Angiotensin Converting Enzyme,
preventing the formation of Angiotensin II, a potent vasoconstrictor and stimulator of
aldosterone.
6. Which of the following is a major contraindication for the use of Metformin in patients
with Type 2 Diabetes?
A. eGFR less than 30 mL/min/1.73m2
B. History of hypertension
C. Body Mass Index (BMI) greater than 30
